The ICMR has issued the key Standard Operating Procedure (SoP) for use of Covaxin under clinical trial mode. The Sop’s stated that “He/she will return to the session site on day 28 or on the date given to him/her for the 2nd dose of Covaxin. All the vaccine recipients will be followed-up for a period of 3 months after the second dose of vaccination.”
The individual that have any allergic history, fever, have an impaired immune system, are on a blood thinner, pregnant, breastfeeding, have received other COVID-19 Vaccine, or any serious health issues according to the Vaccinator, will not be eligible for vaccination. If the recipient suffers through any serious condition any time after vaccination, he/she must inform the vaccinator and report for treatment to a nearest healthcare facility.
India has given emergency use authorisation to Covaxin and Covidshield.
